Submitted by Meri Gibson.
Ongoing research is unlocking new ways to understand and prevent breast cancer recurrence. Here is a powerful glimpse into groundbreaking findings that could reshape survivorship care. Below is a summary of an article that I read in Science Pulse, it makes for remarkably interesting and exciting research reading. The article itself follows my summary.
5-Point Summary
Breast cancer recurrence risk can reach 30% due to dormant tumour cells that evade standard treatments. The possibility of breast cancer returning after treatment remains a significant concern for many survivors.
Dormant cells persist for years in bone marrow, making them hard to detect and treat. The possibility of breast cancer returning after treatment remains a significant concern for many survivors.
A University of Pennsylvania study evaluated Hydroxychloroquine and Everolimus on 51 survivors with dormant cells. The possibility of breast cancer returning after treatment remains a significant concern for many survivors.
Combination therapy eliminated 87% of dormant cells, with no recurrence in three years; each drug alone showed >90% survival rates. The possibility of breast cancer returning after treatment remains a significant concern for many survivors.
Larger trials are planned; this approach could transform post-treatment care by actively reducing recurrence risk.
Article from Science Pulse
The possibility of breast cancer returning after treatment remains a significant concern for many survivors, with recurrence rates reaching as high as 30% because of dormant tumour cells.
These inactive cells can quietly persist in places like the bone marrow for years, escaping conventional therapies designed to attack rapidly dividing cancer cells.
A major study from the University of Pennsylvania may have uncovered a way to finally remove this hidden danger.
In this research, scientists evaluated and knew use of two existing medications. Hydroxychloroquine, commonly used for malaria and autoimmune disorders, and Everolimus, a drug used for certain advanced cancers and immune suppression.
The trial involved 51 breast cancer survivors who were confirmed to have dormant tumour cells. The results were striking. When patients received both drugs together, 87% of dormant cells were eliminated and none of the patients experienced A recurrence within three years of follow up.
Even when taken separately, each drug resulted in survival rates above 90%, suggesting strong therapeutic potential.
A key breakthrough in the study is the understanding that dormant tumour cells behave very differently from active cancer cells. Because these cells remain in a resting state, they are far more difficult to detect and are often untouched by standard treatments.
Yet this same biology also exposes them to weaknesses that drugs targeting cellular survival mechanisms can exploit.
The discovery has the potential to transform how survivorship care is approached. Instead of simply observing patients for signs of relapse, doctors may eventually be able to actively eliminate dormant cells and significantly lower the risk of recurrence.
The research team at the University of Pennsylvania is already preparing larger clinical trials, working to refine dosing strategies and exploring other drug combinations that might further improve outcomes.
If future studies confirm these results, this strategy could become a new cornerstone of post treatment breast cancer care, providing survivors with longer lasting protection and the possibility of greater peace of mind.
